288 related articles for article (PubMed ID: 19239602)
1. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
[TBL] [Abstract][Full Text] [Related]
2. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH
JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
Serrano-Blanco A; Gabarron E; Garcia-Bayo I; Soler-Vila M; Caramés E; Peñarrubia-Maria MT; Pinto-Meza A; Haro JM;
J Affect Disord; 2006 Apr; 91(2-3):153-63. PubMed ID: 16458976
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of paroxetine and imipramine in depressed outpatients.
Melton ST; Kirkwood CK; Farrar TW; Brink DD; Carroll NV
Psychopharmacol Bull; 1997; 33(1):93-100. PubMed ID: 9133757
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE
J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.
Sava FA; Yates BT; Lupu V; Szentagotai A; David D
J Clin Psychol; 2009 Jan; 65(1):36-52. PubMed ID: 19051275
[TBL] [Abstract][Full Text] [Related]
8. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and economic impact of antidepressant medications: a review.
Mitchell J; Greenberg J; Finch K; Kovach J; Kipp L; Shainline M; Jordan N; Anderson C
Am J Manag Care; 1997 Feb; 3(2):323-30; quiz 331. PubMed ID: 10169266
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Serrano-Blanco A; Pinto-Meza A; Suárez D; Peñarrubia MT; Haro JM;
Acta Psychiatr Scand Suppl; 2006; (432):39-47. PubMed ID: 17087814
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
12. Are psychological treatments for depression in primary care cost-effective?
Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
[TBL] [Abstract][Full Text] [Related]
13. Cost savings with nefazodone in treating depression.
Hales RE; Hilty DM; Brunson GH
J Clin Psychiatry; 2002; 63 Suppl 1():48-51. PubMed ID: 11890565
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of paroxetine versus imipramine in major depression.
Bentkover JD; Feighner JP
Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
[TBL] [Abstract][Full Text] [Related]
15. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.
Lapierre Y; Bentkover J; Schainbaum S; Manners S
Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716
[TBL] [Abstract][Full Text] [Related]
16. TCAs or SSRIs as initial therapy for depression?
Tyra JM; Greenawald MH
J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
[No Abstract] [Full Text] [Related]
17. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
Diaz A; Fouilloux C; Ortiz S
Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
[No Abstract] [Full Text] [Related]
18. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Brown MC; Nimmerrichter AA; Guest JF
Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
[TBL] [Abstract][Full Text] [Related]
20. Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine.
Piwowarska J; Dryll K; Szelenberger W; Pachecka J
Acta Pol Pharm; 2008; 65(1):159-64. PubMed ID: 18536191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
